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Abstract
Introduction Currently available treatments for osteoarthritis
(OA) are restricted to nonsteroidal anti-inflammatory drugs,
which exhibit numerous side effects and are only temporarily
effective. Thus novel, safe and more efficacious anti-
inflammatory agents are needed for OA. Naturally occurring
polyphenolic compounds, such as curcumin and resveratrol, are
potent agents for modulating inflammation. Both compounds
mediate their effects by targeting the NF-κB signalling pathway.
Methods We have recently demonstrated that in chondrocytes
resveratrol modulates the NF-κB pathway by inhibiting the
proteasome, while curcumin modulates the activation of NF-κB
by inhibiting upstream kinases (Akt). However, the
combinational effects of these compounds in chondrocytes has
not been studied and/or compared with their individual effects.
The aim of this study was to investigate the potential synergistic
effects of curcumin and resveratrol on IL-1β-stimulated human
chondrocytes in vitro using immunoblotting and electron
microscopy.
Results Treatment with curcumin and resveratrol suppressed
NF-κB-regulated gene products involved in inflammation
(cyclooxygenase-2, matrix metalloproteinase (MMP)-3, MMP-9,
vascular endothelial growth factor), inhibited apoptosis (Bcl-2,
Bcl-xL, and TNF-α receptor-associated factor 1) and prevented
activation of caspase-3. IL-1β-induced NF-κB activation was
suppressed directly by cocktails of curcumin and resveratrol
through inhibition of Iκκ and proteasome activation, inhibition of
IκBα phosphorylation and degradation, and inhibition of nuclear
translocation of NF-κB. The modulatory effects of curcumin and
resveratrol on IL-1β-induced expression of cartilage specific
matrix and proinflammatory enzymes were mediated in part by
the cartilage-specific transcription factor Sox-9.
Conclusions We propose that combining these natural
compounds may be a useful strategy in OA therapy as
compared with separate treatment with each individual
compound.
Introduction
Aging and the proteolytic degradation of extracellular matrix
(ECM) macromolecules in articular cartilage in the joint are
important catabolic events in osteoarthritis (OA) and rheuma-
toid arthritis (RA) [1-3]. In OA, synoviocytes and synovial mac-
rophages produce a wide array of inflammatory mediators
including prostaglandins, reactive oxygen species and proin-
flammatory cytokines such as interleukin 1β (IL-1β), interleukin
6 (IL-6) and tumour necrosis factor α (TNF-α). The proinflam-
matory cytokines in turn stimulate articular chondrocytes and
synoviocytes to produce matrix-degrading enzymes such as
matrix metalloproteinases (MMPs) and proinflammatory
enzymes such as cyclooxygenase-2 (Cox-2). The subsequent
release of prostaglandins promotes, sustains and enhances
additional cytokine production and inflammation, leading to the
destruction and degeneration of the cartilage ECM [4-8]. Sev-Page 1 of 17
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proinflammatory cytokines mediating cartilage degradation in
patients with RA and OA. IL-1β and TNFα participate in these
processes by stimulating chondrocytes and synoviocytes to
produce matrix proteases, chemokines, nitric oxide and
eicosanoids such as prostaglandins and leukotrienes [5,6,8-
10].
Enhanced apoptosis of chondrocytes is now understood to be
a sign of progressive cartilage joint degeneration in OA and in
rheumatic diseases such as gout [11,12]. IL-1β is well known
to induce large-scale apoptosis in chondrocytes in association
with mitochondrial dysfunction and depletion of the cellular
energy production [13-15]. This process is accompanied by
the enhanced synthesis of reactive oxygen species, which in
turn, through their interaction with different signal transduction
pathways, further stimulate apoptosis [13,16,17], disrupt the
mitochondrial membrane potential and ATP production [18],
and induce the activation of caspases [19].
Almost all of the proinflammatory factors involved in the patho-
genesis and progression of OA and RA are regulated by the
transcription factor NF-κB [20]. It is also well known that cel-
lular signalling pathways that involve the Bcl-2/Bax family of
proto-oncogenes, the transcription factor NF-κB, TNF-α and
IL-1β are able to activate apoptosis [21-26]. These pathways
lead to the activation of effector caspases (such as caspase-
3), which cleave cellular proteins. During apoptosis, caspases
target housekeeping, structural and cytoskeletal proteins and
activate inhibitor of caspase-activated deoxyribonuclease or
poly(ADP-ribose) polymerase (PARP). The NF-κB subunits
and IκBα can also be fragmented by caspases, leading to the
repressor form of IκBα [27]. Caspases contribute further to
typical morphological features of apoptosis by destruction of
the nuclear lamina, which is involved in chromatin organization
facilitating heterochromatin condensation at the nuclear enve-
lope. Activation of certain caspases such as caspase-3 plays
a pivotal role in initiating apoptosis [28]. Furthermore, it has
been demonstrated previously that NF-κB is also involved in
part in regulating the master chondrogenic transcription factor
Sox-9 [29]. Sox-9 is actively involved in the regulation of carti-
lage-specific matrix components in chondrocytes such as col-
lagen type II and aggrecan expression, and is thought to play
an important role in chondrocyte differentiation [30-33],
although other co-factors are also known to be important for
collagen type II promotor activation [34,35].
The currently available treatments for OA and RA are only tem-
porarily effective and often result in undesired gastrointestinal
side effects. This highlights the need for clinically safe and effi-
cacious new anti-inflammatory agents. Natural compounds,
such as curcumin and resveratrol, may circumvent the side
effects of nonsteroidal anti-inflammatory drugs and offer new
opportunities for OA and RA therapy.
Curcumin is a potent anti-inflammatory and anti-cancer agent
(Figure 1) [36]. Molecular studies have shown that the anti-
inflammatory effects of curcumin result from inhibition of the
AP-1 and NF-κB pathways: these signalling pathways are acti-
vated in response to IL-1β stimulation and activate Cox-2, a
key inflammatory mediator involved in downstream activation
and release of matrix-degrading MMPs [37-41]. Resveratrol
(trans-3,4' -trihydroxystilbene) is a polyphenolic phytoalexin
(Figure 1) that demonstrates anti-inflammatory, anti-tumour,
immunomodulatory, cardioprotective, anti-oxidative and chem-
opreventive capabilities [13,42-47]. We recently reported that
resveratrol can inhibit IL-1β-induced apoptosis in chondro-
cytes through downregulation of NF-κB regulated anti-apop-
totic gene products mainly through proteasome inhibition [14].
Intracellular signalling is a complex signal communication net-
work, which controls basic biological functions of all cells. Sig-
nalling pathways have been found to malfunction in
chondrocytes and synovial cells in OA and RA. Effective treat-
ment of arthritic conditions will benefit from a strategy that can
simultaneously target multiple cellular signalling pathways to
effectively downregulate inflammation in chondrocytes without
adverse systemic effects. We have proposed that phytochem-
icals such as curcumin and resveratrol target the catabolic
pathways mediated by the NF-κB signal transduction pathway
in cartilage and may be used as clinically safe nutritional fac-
tors for the treatment of OA. The aim of the present study was
to examine the effects of resveratrol and curcumin, in combi-
nation and in isolation on IL-1β-mediated cellular responses
and also on the NF-κB signalling transduction pathway, includ-
ing their potential influence on the master chondrogenic tran-
scription factor Sox-9 and NF-κB-regulated gene products in
primary human chondrocytes.
Figure 1
Chemical structures of resveratrol and curcumin. Curcumin is derived 
from the rhizomes of turmeric (Curcuma longa) and resveratrol is found 
in the skin of red grapes, red berries, peanuts, root extracts of the weed 
Polygonum cuspidatum and numerous other plants. As suggested by 
their chemical structure, both compounds are polyphenols and there-
fore they exhibit similar properties as anti-oxidative and anti-inflamma-
tory agents and can act as free radical scavengers.Page 2 of 17
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Antibodies
Polyclonal anti-collagen type II, monoclonal anti-β1-integrin,
and alkaline phosphatase-linked sheep anti-mouse and sheep
anti-rabbit secondary antibodies were obtained from Chemi-
con International (Temecula, CA, USA). Antibodies to β-actin
and to ubiquitin were from Sigma (Munich, Germany). Anti-
bodies raised against anti-active caspase-3, MMP-9 and
MMP-3 were purchased from R&D Systems (Abingdon, UK).
Cyclooxygenase-2 antibody was obtained from Cayman
Chemical (Ann Arbor, MI, USA). Antibodies against p65, pan-
IκBα, Bcl-2, Bcl-xL and TNF-α receptor-associated factor 1
(TRAF1) were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Antibodies against phospho-specific
IκBα (Ser 32/36) and against anti-phospho-specific p65
(Ser536) were obtained from Cell Technology (Beverly, MA,
USA). Anti-IκBα kinase (anti-IKK)-α and anti-IKK-β were
obtained from Imgenex (Hamburg, Germany). Anti-vascular
endothelial growth factor (anti-VEGF) antibody was pur-
chased from NeoMarkers (Fremont, CA, USA). Monoclonal
anti-PARP antibodies were purchased from Becton Dickinson
(Heidelberg, Germany). Sox-9 antibody was purchased from
Acris Antibodies GmbH (Hiddenhausen, Germany).
All antibodies were used at concentrations and dilutions rec-
ommended by the manufacturer (dilutions ranged from 1:100
for immunomorphological experiments to 1:10,000 for west-
ern blot analysis).
Growth medium and chemicals
Growth medium (Ham's F-12/DMEM (50/50) containing 10%
FCS, 25 μg/ml ascorbic acid, 50 IU/ml streptomycin, 50 IU/ml
penicillin, 2.5 μg/ml amphotericin B, essential amino acids and
L-glutamine) was obtained from Seromed (Munich, Germany).
Trypsin/ethylenediamine tetraacetic acid (EC 3.4.21.4) was
purchased from Sigma. Epon was obtained from Plano (Mar-
burg, Germany). The alkaline phosphatase based APAAP-kit
was purchased from Dako (Carpinteria, CA, USA). Resveratrol
was purchased from Sigma. Curcumin was purchased from
Indsaff (Punjab, India). Resveratrol was prepared as a 100 mg/
ml solution in ethanol and then further diluted in cell culture
medium. Curcumin was diluted in DMSO as a 5,000 μM con-
centration and then further diluted in cell culture medium. IL-
1β was obtained from Strathman Biotech GmbH (Hannover,
Germany).
Peptide aldehydes and the specific proteasome inhibitor N-
Ac-Leu-Leu-norleucinal (ALLN) were obtained from Boe-
hringer Mannheim (Mannheim, Germany).
Chondrocyte isolation and culture
Cartilage tissue samples from healthy femoral head articular
cartilage obtained during joint replacement surgery for femoral
neck fractures were used to isolate primary human articular
chondrocytes [48]. Cartilage slices were digested primarily
with 1% pronase for 2 hours at 37°C and subsequently with
0.2% (v/v) collagenase for 4 hours at 37°C. Primary chondro-
cytes were cultured at a density of 200,000 cells in 60 mm
petri dishes in monolayer culture for a period of 24 hours at
37°C with 5% carbon dioxide. Cartilage samples were derived
from human patients with full informed consent and local eth-
ics committee approval.
Experimental design
Chondrocyte monolayer cultures were washed three times
with serum-starved medium and incubated for 1 hour with
serum-starved medium (0.5% FCS). Serum-starved human
articular chondrocytes were either left untreated, treated with
10 ng/ml IL-1β alone for the indicated time periods, or pre-
treated with 50 μM resveratrol, 50 μM curcumin or 50 μM res-
veratrol and 50 μM curcumin for 4 hours followed by co-treat-
ment with 10 ng/ml IL-1β and 50 μM resveratrol, or 50 μM
curcumin or 50 μM resveratrol and 50 μM curcumin for 24
hours or for the indicated time periods.
Cell viability and proliferation assay
The effects of resveratrol/curcumin on the cytotoxic effects of
IL-1β were examined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT kit; Sigma) uptake method
as previously described [13]. Briefly, for the cell proliferation
assay, 5,000 chondrocytes per well were cultured for 24
hours in a 96-well-plate and then treated with 10 ng/ml IL-1β,
50 μM resveratrol, 50 μM curcumin, 50 μM resveratrol and 50
μM curcumin, or pre-treated with 50 μM resveratrol, 50 μM
curcumin, or 50 μM resveratrol and 50 μM curcumin for 4
hours and then co-treated with 10 ng/ml IL-1β, or left
untreated and evaluated after 24 hours at 37°C.
For evaluation, the medium was removed and 100 μl fresh
medium and 10 μl MTT solution (5 mg/ml PBS, sterile) were
added to each well and incubated for 4 hours at 37°C/5% car-
bon dioxide. Subsequently, 100 μl MTT solubilization solution
was added and the plates incubated until the cells were
bleached. The transmission signal was determined at 570 nm
using a microplate reader (Bio-Rad, Munich, Germany). A
sample without cell loading was used as a baseline value. The
assay was performed in triplicate and the results are provided
as mean values with standard deviations from three independ-
ent experiments.
Poly(ADP-ribose) polymerase cleavage assay
To determine the cleavage products of the DNA repair enzyme
PARP, serum-starved chondrocytes were cultured for 24
hours and then treated with 10 ng/ml IL-1β, with 50 μM res-
veratrol, 50 μM curcumin, and 50 μM resveratrol and 50 μM
curcumin, or pre-treated with 50 μM resveratrol, 50 μM curcu-
min, and 50 μM resveratrol and 50 μM curcumin for 4 hours
and then co-treated with 10 ng/ml IL-1β, or left untreated for
24 hours at 37°C. Whole cell extracts were prepared and
lysed in lysis buffer (20 mM Tris, pH 7.4, 250 mM NaCl, 2 mMPage 3 of 17
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0.01 g/ml aprotinin, 0.005 g/ml leupeptin, 0.4 mM phenyl-
methylsulfonylfluoride, and 4 mM NaVO4). Lysates were spun
at 14,000 rpm for 10 minutes to remove insoluble material,
resolved by 7.5% SDS-PAGE, and probed with PARP anti-
bodies.
NF-κB activation assay
The effect of resveratrol/curcumin on the IL-1β-induced
nuclear translocation of p65 was examined by an immunocyto-
chemical method (the APAAP method) as described previ-
ously [14]. Briefly, chondrocytes seeded on glass plates either
were treated with 10 ng/ml IL-1β for 0, 5, 15 and 30 minutes
alone, or were pre-treated with resveratrol 50 μM and curcu-
min 50 μM for 4 hours and then co-treated with 10 ng/ml IL-
1β for 0, 5, 15 and 30 minutes. After incubation, cells were
fixed for 10 minutes in ice-cold methanol, washed twice (5
minutes) in Tris-buffered saline (TBS) at ambient temperature
and then pre-incubated with normal serum for 10 minutes at
ambient temperature. The cells were incubated with the pri-
mary antibodies (anti-p65) in a humidified chamber overnight
at 4°C. Cells were then rinsed twice with (TBS). After washing
again, incubation with the dual-system bridge antibodies was
performed and cells were treated with the dual-system APAAP
complex for 30 minutes at ambient temperature. Cells were
thoroughly rinsed with (TBS) and counter-stained with new
fuchsin for 30 minutes at ambient temperature. Finally, cells
were washed, air dried and mounted in Kaisers' glycerol gela-
tin prior to examination in an Axiophot 100 light microscope
(Zeiss, Jena, Germany).
Transmission electron microscopy
Samples were fixed for 1 hour with Karnovsky fixative followed
by post-fixation in 1% OsO4 solution (0.1 M phosphate buffer).
Monolayer cell pellets were rinsed and dehydrated in an
ascending alcohol series before being embedded in Epon and
cut on a Reichert-Jung Ultracut E (Darmsadt, Germany).
Ultrathin sections were contrasted with 2% uranyl acetate/
lead citrate. A transmission electron microscope (TEM 10;
Zeiss) was used to examine the cultures.
Electron microscopic evaluation of apoptotic cell death
Serum-starved chondrocytes were exposed to 10 ng/ml IL-1β
alone for 0, 2, 4 and 8 hours or were pre-stimulated with 50/
50 μM resveratrol/curcumin alone for 4 hours and then co-
treated with IL-1β (10 ng/ml) for 1, 12, 24 and 48 hours. Ultra-
thin sections of the samples were prepared and evaluated with
an electron microscope (TEM 10; Zeiss). For statistical analy-
sis, the number of cells with morphological features of apop-
totic cell death was determined by scoring 100 cells from 20
different microscopic fields.
Isolation of chondrocyte nuclei
Cells were trypsinized and washed twice in 1 ml ice-cold PBS.
The supernatant was carefully removed. The cell pellet was re-
suspended in 400 μl hypotonic lysis buffer containing pro-
tease inhibitors and was incubated on ice for 15 minutes. Then
12.5 μl of 10% NP-40 were added and the cell suspension
was vigorously mixed for 15 seconds. The extracts were cen-
trifuged for 1.5 minutes. The supernatants (cytoplasmic
extracts) were frozen at -70°C. Then 25 μl ice-cold nuclear
extraction buffer were added to the pellets and incubated for
30 minutes with intermittent mixing. Extracts were centrifuged
and the supernatant (nuclear extracts) transferred to pre-
chilled tubes for storage at -70°C.
Western blot analysis
To determine the effect of resveratrol/curcumin on IL-1β-
dependent IκBα phosphorylation, IκBα degradation and p65
translocation, whole cell lysates, cytoplasmic and nuclear
extracts of chondrocyte monolayers were prepared and frac-
tioned by SDS-PAGE [14,48,49]. The total protein concentra-
tion of whole cell, nuclear and cytoplasmic extracts (30 μg)
was determined using the bicinchoninic acid assay system
(Uptima; Interchim, Montlucon, France) using BSA as a stand-
ard. Equal quantities (500 ng protein per lane) of total proteins
were separated by SDS-PAGE (5%, 7.5%, 12% gels) under
reducing conditions.
The separated proteins were transferred onto nitrocellulose
membranes. Membranes were pre-incubated in blocking
buffer (5% (w/v) skimmed milk powder in PBS/0.1% Tween
20) for 1 hour, and were incubated with primary antibodies
against p65, IκBα, p-IκBα, VEGF, Cox-2, MMP-3, MMP-9,
active caspase-3, PARP, Bcl-2, Bcl-xL, TRAF1, collagen type
II, Sox-9 and β-Actin (overnight, 4°C). Membranes were
washed three times with blocking buffer, and were incubated
with alkaline phosphatase-conjugated secondary antibodies
for 30 minutes. They were finally washed three times in 0.1 M
Tris, pH 9.5, containing 0.05 M MgCl2 and 0.1 M NaCl. Nitrob-
lue tetrazolium and 5-bromo-4-chloro-3-indoylphosphate (p-
toluidine salt; Pierce, Rockford, IL, USA) were used as sub-
strates to reveal alkaline phosphatase-conjugated specific
antigen-antibody complexes. The density (specific binding) of
each band was measured by densitometry using Quantity One
(Bio-Rad Laboratories Inc., Munich, Germany).
Immune complex kinase assay
To test the effect of resveratrol or curcumin on IL-1β-induced
IKK activation, immune complex kinase assays were per-
formed. The IKK complex was immunoprecipitated from whole
cell lysates with antibodies against IKK-α and IKK-β and sub-
sequently incubated with protein A/G-agarose beads (Pierce,
Ulm, Germany). After 2 hours of incubation, the beads were
washed with lysis buffer and resuspended in a kinase assay
solution containing 50 mM HEPES (pH 7.4), 20 mM MgCl2, 2
mM dithiothreitol, 10 μM unlabelled ATP and 2 mg substrate
GST-IκBα (amino acids 1 to 54), and were incubated at 30°C
for 30 minutes. This was followed by boiling in SDS-PAGE
sample buffer for 5 minutes. The proteins were transferred toPage 4 of 17
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Phosphorylation of GST-IκBα was assessed using a specific
antibody against phospho-specific IκBα (Ser 32/36). To dem-
onstrate the total amounts of IKK-α and IKK-β in each sample,
whole cell lysates were transferred to a nitrocellulose mem-
brane after SDS-PAGE under reducing conditions as
described above. Detection of IKK-α and IKK-β was performed
by immunoblotting with either anti-IKK-α or anti-IKK-β antibod-
ies.
Statistical analysis
The results are expressed as the means ± standard deviation
of a representative experiment performed in triplicate. The
means were compared using Student's t test assuming equal
variances. P < 0.05 was considered statistically significant.
Results
Effects of resveratrol and curcumin on human 
chondrocyte viability and proliferation
In previous studies we have demonstrated that IL-1β-induced
NF-κB activation is cytotoxic to human chondrocytes [13,14].
In the present study we evaluated the effects of resveratrol and
curcumin on this IL-1β-induced cytotoxicity. Proliferation and
viability assays performed with the MTT test demonstrated that
both resveratrol and curcumin significantly decreased the
cytotoxic effects induced by IL-1β (Figure 2). As these data
indicated that both phytochemicals have positive and similar
properties on human chondrocytes, we investigated the
effects of combining resveratrol (50 μM) and curcumin (50
μM) on chondrocyte viability and proliferation. The results
showed a positive effect of combining both phytochemicals
with regard to cell viability and proliferation on inhibiting the IL-
1β-induced cytotoxicity on human chondrocytes (Figure 2).
Resveratrol and curcumin inhibit IL-1β-induced 
mitochondrial changes and apoptosis in chondrocytes
Work from our group previously demonstrated that phyto-
chemical agents such as resveratrol and curcumin suppress
IL-1β-induced apoptosis in human chondrocytes through inhi-
bition of NF-κB-mediated signalling pathways [13,14]. The
objective of the present study was to determine whether cur-
cumin and resveratrol can act synergistically to modulate the
cytotoxic effects of IL-1β in human chondrocytes. Primary
human chondrocytes were exposed to the indicated concen-
trations of resveratrol and/or curcumin alone or with IL-1β as
described in Materials and methods, and the effect of resvera-
trol and/or curcumin on IL-1β-induced apoptosis was exam-
ined at the ultrastructural level using transmission electron
microscopy.
Untreated primary human chondrocytes exhibited a typical
rounded or flattened shape with small cytoplasmic processes,
a large mostly euchromatic nucleus with nucleoli and a well-
structured cytoplasm (Figure 3a, panel a). Treatment of
chondrocytes with 10 ng/ml IL-1β for 1, 12, 24 and 48 hours
led to degenerative morphological changes (Figure 3a, panels
b-e) such as multiple vacuoles, swelling of rough endoplasmic
reticulum, clustering of swollen mitochondria (Figure 3a, panel
c, inset) and degeneration of other cell organelles. After longer
incubation periods (24-48 hours), more severe features of cel-
Figure 2
Effects of resveratrol and curcumin and IL-1β on the viability and proliferation of primary chondrocytes in vitro. To evaluate the effect of curcumin, 
resveratrol and/or IL-1β-induced cytotoxicity, primary chondrocytes were treated with 10 ng/ml IL-1β, 50 μM resveratrol, 50 μM curcumin, 50 μM 
resveratrol and 50 μM curcumin; alternatively they were pre-treated with 50 μM resveratrol, 50 μM curcumin, 50 μM resveratrol and 50 μM curcumin 
for 4 hours and then co-treated with 10 ng/ml IL-1β, or were left untreated and evaluated after 24 hours using the MTT method. In cells treated with 
either curcumin, resveratrol or a combination of both, the cytotoxic effects induced by IL-1β were significantly decreased (*) and cell viability was 
comparable with control cultures.Page 5 of 17
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cell nuclei and multiple vacuoles were observed. The flattened
monolayer chondrocytes became more and more rounded,
lost their microvilli-like processes and became apoptotic (Fig-
ure 3a, panels c and d). Treatment with either resveratrol or
curcumin alone (not shown) or in combination significantly
reduced the cytotoxic and apoptotic effects of IL-1β (Figure
3a, panels f-i).
Quantification of apoptosis was achieved by counting the
number of apoptotic cells in the samples evaluated by trans-
mission electron microscopy (Figure 3b). In untreated control
cultures, the number of cells with apoptotic features in trans-
mission electron microscopy increased with the culture time,
as primary chondrocytes started to de-differentiate and
degenerate. IL-1β treatment of cultures increased the number
of cells with apoptotic features. In contrast, pre-treatment with
the phytochemical agents resulted in cells with fewer apop-
totic features. We deduce that the lower quantities of apop-
totic cells in treated cultures in comparison with control
cultures is due to the fact that the phytochemical agents pre-
vent de-differentiation of the primary chondrocytes by stabiliz-
Figure 3
Effects of resveratrol and curcumin on IL-1β-induced mitochondrial changes and apoptosis in primary chondrocytes. (a) Transmission electron 
microscopy was performed to demonstrate the effects of resveratrol and curcumin on IL-1β-stimulated primary chondrocytes in monolayer culture at 
an ultrastructural level. Untreated control cultures consisted of vital, active chondrocytes containing mitochondria, rough endoplasmic reticulum and 
many other cell organelles (panel a). In contrast, stimulation of chondrocytes with 10 ng/ml IL-1β for 1, 12, 24, and 48 hours resulted in degenerative 
changes in the cells. After 1 hour, chondrocytes became rounded and the nucleus contained more condensed chromatin (panel b). After 12 hours, 
multiple vacuoles, swelling of rough endoplasmic reticulum and clustering of swollen mitochondria were visible (panel c). Inset: arrows demonstrate 
swollen mitochondria. Longer incubations of 24 to 48 hours led to the formation of apoptotic bodies and cell lysis (panels d to e). Treatment of IL-1β-
stimulated primary chondrocytes with resveratrol and curcumin (both at 50 μM), however, inhibited the adverse effects of IL-1β (panels f-i), and after 
48 hours of treatment (panel i) chondrocytes demonstrated large, flattened cells with numerous microvilli-like processes, mitochondria and endo-
plasmic reticulum comparable with control cultures. (b) To quantify apoptosis in these cultures, 100 cells from 20 microscopic fields were counted. 
The number of apoptotic cells was highest in cultures stimulated with IL-1β alone and rose steadily over the entire culture period. In contrast, treat-
ment of IL-1β-stimulated cultures with resveratrol and/or curcumin inhibited the apoptotic effects of IL-1β and the number of apoptotic cells 
remained significantly lower over the entire culture period (*).Page 6 of 17
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Available online http://arthritis-research.com/content/11/6/R165ing and stimulating cell metabolism, thus preventing them from
becoming apoptotic. This demonstrates that curcumin and
resveratrol inhibit the cytotoxic and apoptotic effects induced
by IL-1β in chondrocytes (Figure 3a, b).
Western blot analysis was performed with antibodies against
PARP, since cell degeneration and apoptosis is marked by
enhanced caspase-mediated cleavage of the DNA repair
enzyme PARP (Figure 4). Pre-treatment with either resveratrol,
curcumin or the combination of both inhibited IL-1β-induced
PARP cleavage, and the levels were similar to control cultures.
Taken together, these results indicate that resveratrol and cur-
cumin synergistically exert anti-apoptotic and anti-cytotoxic
effects and counteract IL-1β-induced apoptosis in human
chondrocytes.
Resveratrol and curcumin stimulate the expression of 
anti-apoptotic and inhibit pro-apoptotic gene products 
in chondrocytes
It is known that NF-κB regulates the expression of the anti-
apoptotic proteins Bcl-2, Bcl-xL and TRAF1 [50,51]. To eval-
uate whether resveratrol and curcumin can modulate the
expression of these anti-apoptotic genes products, we exam-
ined IL-1β-stimulated primary human chondrocytes with or
without pre-treatment of resveratrol and curcumin by western
blot analysis (Figure 5a). IL-1β inhibited the expression of Bcl-
2, Bcl-xL and TRAF1 in a time-dependent manner. In contrast
to this, the combinational treatment of resveratrol and curcu-
min stimulated the expression of the above-mentioned anti-
apoptotic proteins in the same manner in chondrocytes (Fig-
ure 5a).
Furthermore, we wanted to know whether resveratrol and cur-
cumin also suppress the IL-1β-induced pro-apoptotic gene
product, activated caspase-3, in the same cell cultures. To
determine this, primary human chondrocytes were incubated
with IL-1β (10 ng/ml) alone for the indicated time or were pre-
incubated with resveratrol and curcumin (50/50 μM) for 4
hours and then co-treated with IL-1β (10 ng/ml) for the indi-
cated time. As shown in Figure 5b, pre-treatment with resver-
atrol and curcumin significantly downregulated the level of
biologically active caspase-3 in IL-1β-stimulated cultures com-
pared with primary human chondrocytes stimulated with IL-1β
alone.
Resveratrol and curcumin inhibit IL-1β-induced NF-κB-
dependent proinflammatory and matrix degradation 
gene products in chondrocytes
We investigated whether resveratrol and curcumin can modu-
late IL-1β-induced NF-κB-regulated gene products involved in
the inflammation and degradation processes in cartilage tis-
sue. It has been shown previously in chondrocytes that IL-1β
stimulation activates Cox-2, VEGF, MMP-3 and MMP-9
expression. We therefore investigated whether both natural
products are able to inhibit the IL-1β-induced expression of
these proteins. Primary human chondrocytes with or without
pre-treatment with resveratrol and curcumin were examined
for IL-1β-induced gene products by western blot analysis
using specific antibodies (Figure 6). IL-1β induced the expres-
sion of Cox-2, MMP-3, MMP-9 and VEGF in a time-dependent
manner, and the combinational treatment of resveratrol and
curcumin inhibited the expression of the above-mentioned pro-
teins in primary chondrocytes (Figure 6). Synthesis of the
housekeeping protein β-actin remained unaffected (Figure 6).
Effect of resveratrol and/or curcumin on IL-1β-induced 
inhibition of collagen type II production in chondrocytes
Serum-starved human articular chondrocytes were cultured
for 24 hours and then treated with 10 ng/ml IL-1β, 50 μM res-
Figure 4
Effects of resveratrol and curcumin on IL-1β-induced apoptosis as demonstrated by poly(ADP-Ribose) polymerase cleavage in primary chondro-cyt s
cytes. As IL-1β-mediated, caspase-induced cleavage of the DNA repair enzyme poly(ADP-Ribose) polymerase (PARP) is a sign of apoptosis, pri-
mary chondrocyte cultures were treated with 10 ng/ml IL-1β, 50 μM resveratrol, 50 μM curcumin, 50 μM resveratrol and 50 μM curcumin, or pre-
treated with 50 μM resveratrol, 50 μM curcumin, 50 μM resveratrol and 50 μM curcumin for 4 hours and then co-treated with 10 ng/ml IL-1β, or left 
untreated for 24 hours. Equal amounts (500 ng protein per lane) of total protein were separated by 7.5% SDS-PAGE and analysed by immunoblot-
ting with anti-PARP antibody. Stimulation of chondrocytes with IL-1β alone induced PARP cleavage. Pre-treatment with either resveratrol, curcumin 
or a combination of both inhibited IL-1β-induced PARP cleavage, however, and levels seen were similar to control cultures. Synthesis of the house-
keeping protein β-actin remained unaffected.Page 7 of 17
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Figure 5
Effects of resveratrol and curcumin on IL-1β-induced NF-κB-dependent gene products in primary chondrocytes. (a) The effect of resveratrol/curcu-
min on IL-1β-induced NF-κB-dependent anti-apoptotic gene products in primary chondrocytes was studied. To determine whether resveratrol and 
curcumin treatment actively stimulates the production of anti-apoptotic gene products, primary chondrocyte cultures were either stimulated for 0, 12, 
24, and 48 hours with 10 ng/ml IL-1β or pre-treated with resveratrol and curcumin (50/50 μM) followed by 0, 12, 24, and 48 hours stimulation with 
10 ng/ml IL-1β. Equal amounts (500 ng protein per lane) of total proteins were separated by 10% SDS-PAGE and analysed by immunoblotting with 
anti-Bcl-2, anti-Bcl-xL and anti-TNF-α receptor-associated factor 1 (anti-TRAF1) antibodies. A time-dependent downregulation of the expression of 
Bcl-2, Bcl-xL and TRAF1 by IL-1β was observed. In contrast, pre-treatment with resveratrol and curcumin resulted in a time-dependent increase of 
these anti-apoptotic proteins. Synthesis of the housekeeping protein β-actin remained unaffected. (b) The effect of resveratrol/curcumin on IL-1β-
induced NF-κB-dependent pro-apoptotic protein caspase-3 was also studied in primary chondrocytes. Whole cell lysates of primary chondrocyte 
cultures were either stimulated for 0, 12, 24, and 48 hours with 10 ng/ml IL-1β or pre-treated with resveratrol and curcumin (50/50 μM) followed by 
0, 12, 24, and 48 hours of stimulation with 10 ng/ml IL-1β-, and evaluated with western blot analysis to examine the effect on the pro-apoptotic pro-
tein caspase-3. Equal amounts (500 ng protein per lane) of total proteins were separated by 12% SDS-PAGE and analysed by immunoblotting with 
an antibody against active caspase-3. Stimulation of the cultures with IL-1β resulted in a time-dependent activation of caspase-3. In contrast, combi-
national treatment of resveratrol and curcumin inhibited caspase-3 activation in a time-dependent manner. Synthesis of the housekeeping protein β-
actin was not affected.
Figure 6
Effects of resveratrol and curcumin on IL-1β-induced NF-κB-dependent proinflammatory and matrix-degrading gene products in primary chondro-cyt s
cytes. To evaluate whether resveratrol and curcumin exert time-dependent effects on IL-1β-induced NF-κB-dependent expression of proinflammatory 
and matrix-degrading gene products, primary chondrocyte cultures were either stimulated for 0, 12, 24, and 48 hours with 10 ng/ml IL-1β or pre-
treated with resveratrol and curcumin (50 μM each) followed by 0, 12, 24, and 48 hours of stimulation with 10 ng/ml IL-1β; after extraction of whole 
cell lysates (500 ng protein per lane), they were probed for the expression of matrix metalloproteinase (MMP)-3, MMP-9, cylcooxygenase-2 (Cox-2) 
and vascular endothelial growth factor (VEGF) by western blot analysis. Stimulation of IL-1β alone consistently resulted in time-dependent produc-
tion of MMP-3, MMP-9, Cox-2 and VEGF. In contrast, pre-treatment with resveratrol and curcumin downregulated MMP-3, MMP-9, Cox-2 and VEGF 
time dependently. Synthesis of the housekeeping protein β-actin was unaffected.
Available online http://arthritis-research.com/content/11/6/R165veratrol, 50 μM curcumin, and with 50 μM resveratrol and 50
μM curcumin, or were pre-treated with 50 μM resveratrol, 50
μM curcumin, and 50 μM resveratrol and 50 μM curcumin for
4 hours and then co-treated with 10 ng/ml IL-1β, or left
untreated and evaluated after 24 hours (Figure 7). Treatment
of chondrocytes with 50 μM curcumin, with 50 μM resveratrol
or with 50 μM resveratrol and 50 μM curcumin resulted in a
stimulation of collagen type II production. Primary human
chondrocytes stimulated with IL-1β alone showed a significant
downregulation of synthesis of collagen type II. In contrast,
pre-treatment of chondrocytes with the phytochemical agents
followed by stimulation with IL-1β resulted in an inhibition of
cytokine-induced effects on collagen type II production (Figure
7a, panel I). Interestingly, co-treatment of the chondrocytes
with combinations of the two phytochemical agents increased
the levels of these proteins more than each agent by itself.
Figure 7
Effects of resveratrol and curcumin on IL-1β-induced inhibition of collagen type II and Sox-9 production in chondrocytes. To evaluate the effects of 
resveratrol and curcumin on IL-1β-stimulated chondrogenic inhibition in primary chondrocytes, whole cell lysates (500 ng protein per lane) were 
probed with antibodies to (a) collagen type II (panel I), as the most abundant cartilage-specific extracellular matrix protein, and (b) the chondrogenic-
specific transcription factor Sox-9 (panel I). Cultures were treated with 10 ng/ml IL-1β, 50 μM resveratrol, 50 μM curcumin, 50 μM resveratrol and 
50 μM curcumin, or were pre-treated with 50 μM resveratrol, 50 μM curcumin, 50 μM resveratrol and 50 μM curcumin for 4 hours and then co-
treated with 10 ng/ml IL-1β, or left untreated for 24 hours. Untreated cultures had strong (a) collagen type II and (b) Sox-9 and stimulation with IL-1β 
alone greatly reduced collagen type II as well as Sox-9 production. However, pre-treatment of the cultures with resveratrol, curcumin or a combina-
tion of both inhibited the adverse effects of IL-1β and the chondrocytes produced large quantities of collagen type II and Sox-9 at levels similar to 
control cultures. This was confirmed by quantitative densitometry (a, panel II and b, panel II). The mean values and standard deviations from three 
independent experiments are shown. White, grey and solid bars represent different molecular forms of collagen type II. Synthesis of the housekeep-
ing protein β-actin remained unaffected.Page 9 of 17
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chondrocyte nucleus
Sox-9 is a master specific transcription factor that controls the
expression of chondrocyte-specific ECM protein genes and
plays a pivotal role in chondrocyte differentiation [52]. To test
the hypothesis that phytochemicals are able to activate the
transcription factor Sox-9 in human chondrocytes, monolayer
cultures of human chondrocytes were either left unstimulated
or stimulated with resveratrol and/or curcumin or were pre-
treated with resveratrol and/or curcumin (50/50 μM) for 4
hours and then stimulated with IL-1β for 24 hours, and the cell
lysates were analysed by immunoblotting.
The results demonstrated that resveratrol and/or curcumin
stimulated Sox-9 expression and inhibited the IL-1β-induced
decreased Sox-9 expression (Figure 7b, panel I). Because
these data indicate that both phytochemicals have similar
properties, we further investigated the cumulative role of res-
veratrol (50 μM) and curcumin (50 μM) on IL-1β-induced inhi-
bition of Sox-9 expression in chondrocytes. The results
suggest that signalling from exposure to extracellular resvera-
trol and curcumin converge to influence the activity of tran-
scription factors such as Sox-9, which are necessary for the
expression of cartilage matrix genes (Figure 7b). Quantitative
analysis (Figure 7a, panel II and 7b, panel II) of the western blot
results confirmed that resveratrol and/or curcumin increase
the expression of collagen type II (Figure 7a, panel II) and Sox-
9 (Figure 7b, panel II) and inhibit the IL-1β-induced decrease
in collagen type II and Sox-9 expression. Data shown are rep-
resentative of three independent experiments.
Resveratrol and curcumin block IL-1β-induced nuclear 
translocation of NF-κB as revealed by APAAP
NF-κB is an important transcriptional regulator of inflammatory
cytokines gene expression and plays a crucial role in inflamma-
tory responses. After phosphorylation, ubiquitination and deg-
radation of IκBα, the NF-κB fragment is translocated to the
nucleus where it binds and activates the promoter of target
genes. This translocation of NF-κB to the nucleus is necessary
for regulation of gene expression by NF-κB [20].
Primary human chondrocytes were either left untreated (Figure
8a, A), or treated with 10 ng/ml IL-1β alone for 5, 15 and 30
minutes (Figure 8a, panels B-D), or pre-treated with resveratrol
and/or curcumin (50/50 μM) for 4 hours and then stimulated
with IL-1β for the same time periods (Figure 8a, panels E-G).
In untreated control cultures, only cytoplasmic labelling of NF-
κB was observed (Figure 8a, panel A). After 15 minutes of
treatment, IL-1β-stimulated chondrocytes showed a clear and
positive labelling for activated NF-κB in the nuclei and to a
lesser extent in the cytoplasm of chondrocytes (Figure 8a,
panels B-D). Chondrocytes that were pre-treated with resver-
atrol and curcumin 50/50 μM (4 hours) and then co-treated
with IL-1β and resveratrol and curcumin showed positive stain-
ing in the cytoplasm and showed a clearly decreased, nuclear
NF-κB staining (Figure 8a, panels E-G).
Resveratrol and curcumin inhibit NF-κB activation 
caused by IL-1β in a concentration-dependent and time-
dependent manner in chondrocytes
To examine whether resveratrol and curcumin block the IL-1β-
induced activation of NF-κB, nuclear protein extracts from
serum-starved chondrocytes were probed for the phosphor-
ylated form of the p65 NF-κB subunit after pre-treatment with
50 μM resveratrol and 50 μM curcumin for the indicated times
followed by 10 ng/ml IL-1β stimulation for 30 minutes (Figure
8b, panel I). Furthermore, chondrocytes were pre-incubated
with the indicated concentrations of resveratrol and curcumin
for 4 hours followed by co-treatment with 10 ng/ml IL-1β and
resveratrol and curcumin for 30 minutes (Figure 8b, panel II).
The western blot results confirmed that co-treatment of resver-
atrol and curcumin had no effect on NF-κB activation. Resver-
atrol and curcumin, however, inhibited IL-1β-induced NF-κB
activation in a time-dependent (Figure 8b, panel I) and a con-
centration-dependent (Figure 8b, panel II) manner.
Resveratrol but not curcumin inhibits IL-1β-induced IκBα 
degradation
Resveratrol and curcumin inhibited IL-1β-induced activation of
NF-κB and its translocation to the chondrocyte nucleus. We
therefore examined the upstream mechanisms of NF-κB acti-
vation by IL-1β in chondrocytes. It is well known that an impor-
tant pre-requisite for the activation of NF-κB is the
phosphorylation and degradation of IκBα, the natural blocker
of NF-κB [53,54].
To test whether inhibition of IL-1β-induced NF-κB activation
occurs through inhibition of IκBα degradation or through inhi-
bition of IKK activation, we treated chondrocyte cultures for 8
hours with 10 ng/ml IL-1β alone or with 100 μM of the specific
proteasome inhibitor ALLN [55], which prevents the degrada-
tion of phosphorylated IκBα by the 26S proteasome. Other
serum-starved human articular chondrocytes were pre-stimu-
lated with 50 μM resveratrol, 50 μM curcumin or 100 μM
ALLN alone for 4 hours and then co-treated with IL-1β (10 ng/
ml) for 8 hours. Additionally, other serum-starved human artic-
ular chondrocytes were pre-stimulated with 50 μM resveratrol
or 50 μM curcumin alone for 4 hours and then co-treated with
IL-1β (10 ng/ml) for 8 hours. Some cultures were left
untreated and evaluated after 12 hours. The activation of
pIκBα in the cytoplasm of the chondrocytes was determined
by western blot analysis using anti-IκBα and anti-β-actin (con-
trol) antibodies. IL-1β induced IκBα degradation in untreated
cultures, but IL-1β could not induce IκBα degradation in res-
veratrol pre-treated chondrocytes - in contrast to curcumin
pre-treated cells (Figure 9). Taken together, these results sug-
gest that in contrast to curcumin resveratrol blocks IL-1β-
induced IκBα degradation. Data shown are representative of
three independent experiments.Page 10 of 17
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ubiquitination of IκBα
Next we determined whether resveratrol or curcumin affected
the IL-1β-induced IκBα ubiquitination that leads to IκBα deg-
radation. We treated some chondrocyte cultures with 10 ng/
ml IL-1β alone or with 100 μM ALLN for 8 hours. Other serum-
Figure 8
Inhibition of IL-1β-induced NF-κB activation and nuclear translocation by resveratrol and curcumin in primary chondrocytes using APAAPi -  tiv ti  and nuclear translocation by resveratrol and curcumin in primary chondrocytes using APA P. (a) Human 
chondrocyte cultures either served as controls (panel A, not treated) or treated either with 10 ng/ml IL-1β 5, 15 and 30 minutes alone or pre-treated 
with 50 μM resveratrol and 50 μM curcumin for 4 hours and then co-treated with 10 ng/ml IL-1β for 5, 15 and 30 minutes, before immunolabelling 
with phospho-p65 antibodies. In control cells, anti-phospho-p65 labelling was restricted to the cytoplasm (panel A). Cells treated with IL-1β alone 
revealed nuclear translocation of phospho-p65 (panels B-D) that was inhibited by co-treatment with resveratrol and curcumin (panels E-G). Data 
shown are representative of three independent experiments. A-G: × 160, bar = 50 μm. (b) Panel I: western blot analysis with IL-1β-treated chondro-
cyte nuclear extracts. Serum-starved chondrocytes were pre-incubated with 50 μM resveratrol and 50 μM curcumin for 5, 10, 20, 30, 40 and 50 
minutes, co-treated with 10 ng/ml IL-1β for 30 minutes, and then probed for phospho-p65 by western blot analysis using antibodies to phospho-
specific p65 and poly(ADP-Ribose) polymerase (PARP) (control). Resveratrol and curcumin pre-treatment inhibited IL-1β-induced NF-κB activation 
in a time-dependent manner. NF-κB nuclear translocation was inhibited completely after 50 minutes of pre-treatment with resveratrol and curcumin. 
Panel II: serum-starved human chondrocytes were pre-incubated with resveratrol and curcumin at various concentrations (5 μM, 10 μM, 20 μM, 30 
μM, 40 μM and 50 μM each) for 4 hours followed by 10 ng/ml IL-1β stimulation for 30 minutes. The nuclear extracts (500 ng protein per lane) were 
probed for phospho-p65 by western blot analysis using antibodies to phospho-specific p65 and PARP (control). A concentration-dependent inhibi-
tion of NF-κB nuclear translocation was observed. At a concentration of 40 μM resveratrol and 40 μM curcumin, NF-κB nuclear translocation was 
completely inhibited. The inhibition of NF-κB nuclear translocation by resveratrol and curcumin is therefore concentration as well as time dependent. 
Synthesis of PARP remained unaffected in nuclear extracts.Page 11 of 17
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with 50 μM resveratrol, 50 μM curcumin or 100 μM ALLN
alone for 4 hours and then co-treated with IL-1β (10 ng/ml) for
8 hours. Other serum-starved human articular chondrocytes
were pre-stimulated with 50 μM resveratrol or 50 μM curcu-
min alone for 4 hours and then co-treated with IL-1β (10 ng/
ml) for 8 hours. Some cultures were left untreated and evalu-
ated after 12 hours. Western blot analysis using an antibody
that detects IκBα indicated that IL-1β induced IκBα ubiquiti-
nation, as indicated by high molecular weight bands, and that
mainly resveratrol, but not curcumin, suppressed this ubiquiti-
nation (Figure 10). Mainly resveratrol, but not curcumin, there-
fore inhibited IL-1β-induced NF-κB activation by inhibiting
phosphorylation, ubiquitination, and degradation of IκBα (Fig-
ure 10). Data shown are representative of three independent
experiments.
Resveratrol does not inhibit IL-1β-induced IKK activation
As we could demonstrate, resveratrol inhibits the degradation
and ubiquitination of IκBα. We now further evaluated the
effect of resveratrol on IL-1β-induced IKK activation, which is
required for IL-1β-induced phosphorylation of IκBα. The
Figure 9
Effects of resveratrol and curcumin treatment on IL-1β-induced IκBα degradationi I ti . Serum-starved human chondrocytes were pre-treated with 10 ng/
ml IL-1β alone for 4 hours, or with 100 μM N-Ac-Leu-Leu-norleucinal (ALLN) for 30 minutes, or pre-treated with 50 μM resveratrol, 50 μM curcumin 
or 100 μM ALLN alone for 4 hours and then co-treated with IL-1β (10 ng/ml) for 8 hours. Other serum-starved chondrocytes were pre-treated with 
50 μM resveratrol or 50 μM curcumin alone for 4 hours and then co-treated with IL-1β (10 ng/ml) for 8 hours. Some cultures were left untreated and 
evaluated after 12 hours. Cytoplasmic extracts (500 ng protein per lane) were fractionated and then subjected to western blotting with phosphospe-
cific IκBα antibody. The data demonstrate that resveratrol (but not curcumin) inhibits IL-1β-induced IκBα degradation. Data shown are representa-
tive of three independent experiments. The same membrane was re-blotted with antibodies to β-actin.
Figure 10
Effects of resveratrol and curcumin treatment on IL-1β-induced IκBα ubiquitination. Serum-starved human chondrocytes were pre-treated with 10 
ng/ml IL-1β alone for 4 hours, or 100 μM N-Ac-Leu-Leu-norleucinal (ALLN) for 30 minutes, or pre-treated with 50 μM resveratrol, 50 μM curcumin or 
100 μM ALLN alone for 4 hours and then co-treated with IL-1β (10 ng/ml) for 8 hours. Other serum-starved chondrocytes were pre-treated with 50 
μM resveratrol or 50 μM curcumin alone for 4 hours and then co-treated with IL-1β (10 ng/ml) for 8 hours. Some cultures were left untreated and 
evaluated after 12 hours. Cytoplasmic extracts were immunoprecipitated with an antibody against IκBα and subjected to western blot analysis using 
a monoclonal anti-ubiquitin antibody. Resveratrol (but not curcumin), stabilized IL-1β-induced ubiquitination of IκBα. Data shown are representative 
of three independent experiments.Page 12 of 17
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1β activated IKK as early as 5 minutes after IL-1β treatment,
but that resveratrol did not inhibit IL-1β-induced activation of
IKK (Figure 11a, panel I). IL-1β or resveratrol had no direct
effect on the expression of IKK protein (Figure 11a, panels II
and III).
Curcumin but not resveratrol inhibits IL-1β-induced IκBα 
kinase activation
Since we could demonstrate that curcumin inhibits the phos-
phorylation of IκBα, we then evaluated whether curcumin has
an effect on IL-1β-induced IKK activation, which is required for
IL-1β-induced phosphorylation of IκBα. Curcumin completely
suppressed IL-1β-induced activation of IKK (Figure 11b, panel
I). IL-1β or curcumin had no direct effect on the expression of
IKK protein (Figure 11b, panels II and III).
Discussion
The aim of the present study was to determine if the anti-
inflammatory and anti-apoptotic effects of resveratrol and cur-
cumin in primary human chondrocytes are mediated by similar
signalling mechanisms and whether combining these natural
compounds has a synergistic effect on IL-1β-mediated cellular
responses, NF-κB-mediated signal transduction pathways
and regulation of NF-κB-regulated gene expression.
The study leads to the following findings: IL-1β-induced sup-
pression of chondrocytes viability and proliferation is revoked
by resveratrol and curcumin pre-treatment. Stimulation of
chondrocytes with IL-1β results in morphological alterations
(that is, swollen mitochondria, dilated endoplasmic reticulum
and apoptosis) that were abolished through pre-treatment
with resveratrol and curcumin. Co-treatment of the IL-1β-stim-
ulated cells with both resveratrol and/or curcumin inhibits acti-
vation of PARP cleavage. Resveratrol potentiates the anti-
inflammatory and anti-apoptotic effects of curcumin on IL-1β-
stimulated chondrocytes, and this correlates with downregula-
tion of NF-κB-specific gene products that are known to medi-
ate inflammation, degradation and apoptosis of chondrocytes
in OA. Additionally, both resveratrol and/or curcumin sup-
pressed IL-1β-induced downregulation of the cartilage-spe-
cific ECM component collagen type II and of the cartilage-
specific master transcription factor Sox-9. The activation and
translocation of p65 from the cytoplasm to the nucleus could
be inhibited clearly by resveratrol and curcumin in IL-1β-stimu-
lated human chondrocytes. Both resveratrol and curcumin
inhibited NF-κB activation in a concentration-dependent and
Figure 11
Effects of resveratrol and curcumin treatment on IL-1β-induced IκB kinase activation. Serum-starved primary human chondrocytes were pre-treated 
with (a) 50 μM resveratrol or (b) 50 μM curcumin for 4 hours and then co-treated with IL-1β (10 ng/ml) for the indicated times. Whole cell extracts 
were immunoprecipitated with an antibody against IκB kinase (IKK)-α and analysed by an immune complex kinase assay. To examine the effect of 
curcumin on the expression level of IKK proteins, whole cell extracts (500 ng protein per lane) were fractionated by SDS-PAGE and examined using 
western blot analysis with anti-IKK-α and anti-IKK-β antibodies. Data shown are representative of three independent experiments. The results demon-
strate that resveratrol does not affect IL-1β-induced IKK activation.Page 13 of 17
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by resveratrol occurred mainly through the accumulation of
phosphorylated IκBα, ubiquitinated IκBα and inhibition of pro-
teasome activity - in contrast to this, in the case of curcumin it
was mainly caused through inhibition of IKK activation.
Proinflammatory cytokines such as TNF-α and IL-1β have
been shown to mediate cartilage degradation and apoptosis in
chondrocytes in degenerative joint diseases such as RA and
OA in humans as well as in animals. Indeed, cytokine-mediated
apoptosis of chondrocytes is believed to play a key role in the
pathogenesis of OA [56-59]. These proinflammatory cytokines
are produced by activated synoviocytes, macrophages and
chondrocytes [60]. They are well known to activate the ubiqui-
tous transcription factor NF-κB, which leads to further produc-
tion and upregulation of proinflammatory cytokines and
enzymes such as Cox-2 and MMPs, which in turn produce
prostaglandins and degrade ECM macromolecules leading to
cartilage degradation and further joint inflammation [40].
Although numerous effects have been described for resvera-
trol and curcumin, however, the mechanisms responsible for
their anti-inflammatory effects in chondrocytes are not yet
clear.
Activation of NF-κB provides the potential link between inflam-
mation and hyperplasia during OA and RA in the joint [61]. The
use of a specific NF-κB inhibitor has been reported to result in
a significant decrease in joint swelling in mice with collagen-
induced arthritis [62]. NF-κB therefore represents an impor-
tant target for therapeutic strategies aimed at the prophylactic
treatment of inflammatory disorders, such as OA and RA.
Resveratrol and curcumin are anti-inflammatory dietary phyto-
chemicals that have previously been shown to antagonize
some catabolic effects of TNFα and IL-1β via inhibition of NF-
κB in different cell types [13,63-67]. We have previously dem-
onstrated that in chondrocytes resveratrol inhibits NF-κB
through suppression of the proteasome activity [14], and this
leads to the accumulation of phosphorylated IκBα and inhibi-
tion of p65. Curcumin has been shown to inhibit NF-κB activa-
tion in chondrocytes [40] and other cell lines of various origins
[68]. However, whether curcumin can also inhibit NF-κB acti-
vation through inhibition of the proteasome activity or IKK acti-
vation in chondrocytes has not been previously reported.
We found that inhibition of IKK by curcumin, which is needed
for NF-κB activation, led to inhibition of phosphorylation of
both IκBα and p65 but the proteasome was not affected by
curcumin. We also found that resveratrol and curcumin in
combination stimulated several genes that are regulated by
NF-κB, including anti-apoptotic gene products (Bcl-2, Bcl-xL
and TRAF1). Resveratrol and curcumin inhibited pro-apoptotic
proteins (caspase-3, PARP) and matrix degrading gene prod-
ucts (MMP3 and MMP-9), and angiogenesis and inflammation
gene products (VEGF and Cox-2). It has been reported that
the expression of Bcl-2 and Bcl-xL is known to be regulated by
NF-κB and can block cell death induced by a variety of agents
[69,70]. In the present study we could indeed demonstrate the
synergistic effects of naturally occurring polyphenolic com-
pounds resveratrol and curcumin on NF-κB activation and the
regulation of expression of its target gene products.
It is not clear whether these effects of resveratrol and curcu-
min are mediated only by targeting NF-κB; on the contrary, it
is absolutely possible that resveratrol and curcumin mediate
their effects by targeting more than one cell signalling pathway
[71]. However, if this was the case, then the beneficial effects
that resveratrol and curcumin might have in OA and RA ther-
apy would be further emphasized, as recent reports have dem-
onstrated that multi-targeted therapy has a better chance of
success against inflammation and cancer compared with ther-
apies that aim for a single target [72,73].
It is well known that the cartilage-specific transcription factor
Sox-9 is required for expression of cartilage-specific ECM
genes [74-76]. We also observed a reduction in collagen type
II and Sox-9 expression in chondrocytes after treatment with
IL-1β, consistent with previous reports of articular chondro-
cytes from our and other laboratories [77]. We further
observed, however, an inhibition of IL-1β-induced downregu-
lation of collagen type II and Sox-9 expression by pre-treating
the cells with resveratrol or curcumin. Moreover, we extended
these studies by pre-treating the cells with a combination of
resveratrol and curcumin, revealing further inhibition of IL-1β-
induced reduction in collagen type II and Sox-9 expression
compared with each compound alone. These changes in
expression of collagen type II and Sox-9 in response to resver-
atrol and curcumin are probably due to alternate modes of reg-
ulation, independent of changes in NF-κB. Consistent with
these findings, previous studies from other laboratories have
shown that cytokines partially reduce Sox-9 protein levels over
a period of 8 hours through a NF-κB-dependent, post-tran-
scriptional mechanism in mouse chondrocytes [78,79] - dem-
onstrating how active transcription factors, sharing common
co-factors, regulate gene expression.
Conclusions
The results presented here suggest that the anti-inflammatory
and anti-apoptotic effects of resveratrol and/or curcumin are
mediated through crosstalk among the inhibition of the IKK-
induced and proteasome-induced NF-κB pathway, which are
activated by a wide variety of proinflammatory agents. Based
on these results, we conclude that both resveratrol and curcu-
min are direct inhibitors of IKK and the proteasome; through
this inhibition they block NF-κB and NF-κB-regulated gene
expression (Figure 12). However, since a large variety of intra-
cellular signalling pathways interact and converge in chondro-
cytes, we do not exclude that both resveratrol and curcumin
may have additional molecular targets in these cells. Conse-Page 14 of 17
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Available online http://arthritis-research.com/content/11/6/R165quently they may also influence inflammatory and apoptotic
pathways using other mechanisms.
Further in vitro and in vivo studies in animals and humans will
be required to determine the full potential of the synergistic
effects of both resveratrol and curcumin and their potential for
the prevention and treatment of OA and RA.
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